Objectives: The objective of this presentation is to explore and evaluate innovative treatment modalities for keloids, with a focus on intralesional chemotherapy and contact cryotherapy. By examining the limitations of traditional approaches such as surgery and intralesional corticosteroids, this session aims to highlight the mechanisms, efficacy, and safety profiles of these emerging therapies. Additionally, the presentation seeks to provide clinicians with evidence-based insights and practical guidance on integrating these novel treatments into clinical practice to achieve superior patient outcomes and
Introduction: The objective of this presentation is to explore and evaluate innovative treatment modalities for keloids, with a focus on intralesional chemotherapy and contact cryotherapy. By examining the limitations of traditional approaches such as surgery and intralesional corticosteroids, this session aims to highlight the mechanisms, efficacy, and safety profiles of these emerging therapies. Additionally, the presentation seeks to provide clinicians with evidence-based insights and practical guidance on integrating these novel treatments into clinical practice to achieve superior patient outcomes and
Materials / method: Intralesional chemotherapy and contact cryotherapy have emerged as promising yet underutilized alternatives in the management of keloids. Intralesional chemotherapy, employing agents such as 5-fluorouracil, vincristine, and docetaxel, directly targets fibroblast proliferation and collagen synthesis, providing a mechanism-driven approach to reducing keloid size and alleviating symptoms. Recent clinical studies have shown high response rates in appropriately selected patients, with significantly lower recurrence rates compared to traditional therapies.
Results: Contact cryotherapy results in cold-induced tissue destruction. Unlike traditional spray cryotherapy, contact cryotherapy achieves uniform tissue freezing while sparing surrounding healthy skin, leading to improved clinical outcomes. Cryotherapy not only reduces keloid volume effectively but also enhances symptom relief and prevents recurrence when used as a monotherapy or in combination with other modalities.
Conclusion: This presentation will review the evidence supporting the efficacy and safety of these innovative treatment modalities, highlighting their potential to transform the current paradigm of keloid management. By leveraging the unique mechanisms of intralesional chemotherapy and the precision of contact cryotherapy, clinicians can achieve superior outcomes, reduce recurrence rates, and improve the quality of life for patients with keloids.
利益冲突声明
您有否接受任何资金来支持研究这个主题?
否
您是否接受过关于这项研究的任何酬金或其他报酬?
否
你是否和任何与您的研究所涉及的药物,材料或工具有密切联系的实体存在财务关系?
否
你是否拥有或者您已经为您此研究中的工具,药物或材料申请任何专利?
否
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。